Related Experiment Video
Updated: Mar 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy
Yuichi Takashi1, Yuka Kinoshita1, Michiko Hori1
1a Division of Nephrology and Endocrinology , The University of Tokyo Hospital , Bunkyo-ku , Tokyo , Japan.
Purpose:
Fibroblast growth factor 23 (FGF23) is a hormone regulating phosphate metabolism. Excessive actions of FGF23 cause several types of FGF23-related hypophosphatemic rickets/osteomalacia. Recently, it was reported that FGF23 levels were independently correlated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). In addition, FGF23 was also shown to cause cardiac hypertrophy directly acting on cardiomyocytes. However, there is no study indicating the correlation between FGF23 and LVH in adult patients with FGF23-related hypophosphatemic rickets/osteomalacia. Therefore, we examined the existence of LVH in these patients.
Materials And Methods:
We recruited consecutive 24 patients with FGF23-related hypophosphatemic diseases. Their serum intact FGF23 levels and the parameters associated with LVH, including left ventricular mass index (LVMI), relative wall thickness (RWT), Sokolow-Lyon voltage, and Cornell product, were measured. The correlations between FGF23 and these parameters were examined.
Results:
The participants did not show LVH on the whole. In addition, no significant correlation was observed by these examinations.
Conclusion:
It seems unlikely that FGF23 levels are the apparent determinant of the cardiac mass in patients with FGF23-related hypophosphatemic rickets/osteomalacia.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Heart Failure III: Clinical Manifestations
Inborn Errors of Metabolism
Cardiomyopathy IV: Restrictive Cardiomyopathy
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

